These results support the additional benefit of tiragolumab combined with atezolizumab and chemotherapy for patients with treatment-naive, locally advanced unresectable or metastatic oesophageal cancer. Further validation of tiragolumab plus atezolizumab and chemotherapy has been performed in the phase 3 SKYSCRAPER-08 trial (NCT04540211).
[Articles] First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial
The Lancet Oncology | | Jong-Mu Sun, Yee Chao, Sung-Bae Kim, Sun Young Rha, Thomas R Jeffry Evans, Andrew H Strickland, Zev Wainberg, Ian Chau, Sharon Pelles-Avraham, Jaffer Ajani, Ritu Malhotra, Qingyuan Liu, Sijing Li, Edward Cha, Melania Kalaitzidou, Xiayu Huang, Simon Allen, Chih-Hung Hsu
Topics: blood-cancer, esophageal-cancer, immunotherapy, chemotherapy, clinical-trials